Vaishali Pharma Limited reported a net profit of ₹403.17 lakh for the financial year ended March 31, 2026, a significant increase from ₹81.74 lakh in the previous year. Revenue from operations rose to ₹10,877.23 lakh for FY26, compared to ₹9,902.56 lakh in FY25. The company’s Board of Directors approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026, in a meeting held on May 30, 2026.

For the quarter ended March 31, 2026, the company recorded a net profit of ₹26.64 lakh, while revenue from operations stood at ₹2,692.71 lakh. Total income for the quarter was ₹2,818.91 lakh. The earnings per share (EPS) for the year ended March 31, 2026, was reported at ₹0.31 on a basic and diluted basis, up from ₹0.06 in the previous year.

Standalone Financial Performance

The standalone financial statements for the year ended March 31, 2026, reflect a growth in profitability. Total expenses for the year were ₹10,722.07 lakh, up from ₹10,100.52 lakh in the prior year. Finance costs increased to ₹196.25 lakh from ₹158.30 lakh in FY25. The profit before tax for the year stood at ₹538.69 lakh, compared to ₹122.58 lakh in the previous year.

Auditor’s Observations

The statutory auditors, Raman S. Shah & Associates, issued an audit report with an unmodified opinion on the financial results. However, the auditors highlighted a matter regarding current assets. The company has trade receivables of ₹5,077.26 lakh, deposits, loans, and advances of ₹3,199.85 lakh, and other current assets of ₹2,344.86 lakh. These balances include a substantial value of receivables outstanding for more than three years. The auditors stated they are unable to comment on adjustments that may be required to the carrying value of these assets and the consequential impact on the financial statements. Trade receivables amounting to ₹226.90 lakh were written off during the year.

Consolidated Results and Associate

The consolidated financial results include the accounts of associate Kesar Pharma Limited, which the company acquired in September 2025. The share of profit from the associate for the year ended March 31, 2026, was ₹13.31 lakh. The consolidated net profit for the year was ₹416.48 lakh. The company noted that comparative consolidated figures for the previous year are not presented as consolidation was not applicable prior to the acquisition.

Vaishali Pharma has approved the re-appointment of its Managing Director, Whole-Time Director, and an Independent Director for five-year terms. The Board of Directors met on May 23, 2026, to ratify the appointments, which are subject to the approval of the company's shareholders. The decisions ensure continuity in leadership as the company continues its operations in the pharmaceutical industry.

The Board re-appointed Mr. Atul Arvind Vasani as Managing Director, a position he has held since the company's incorporation. His term is set for five consecutive years from May 23, 2026, to May 22, 2031. Mrs. Jagruti Vasani was also re-appointed as Whole-Time Director for a similar five-year term ending on May 22, 2031. Additionally, the Board approved the second term of Mr. Pratik Vikram Jakhelia as an Independent Director for five years from September 30, 2026, to September 29, 2031.

Director Profiles and Terms

The re-appointments follow the recommendations of the Nomination and Remuneration Committee. The detailed profiles and terms of the appointed directors are outlined below:

Mr. Atul Vasani, aged 62, is the Promoter, Chairman, and Managing Director with around three decades of experience in the pharmaceutical industry. Mrs. Jagruti Vasani, aged 60, is the Promoter and Whole-Time Director who oversees the Human Resource Department. Mr. Pratik Vikram Jakhelia is a Fellow Member of the Institute of Chartered Accountants of India with 25 years of experience in accounts and education.

Disclosures and Compliance

The company disclosed that Mrs. Jagruti Vasani is the wife of Mr. Atul Vasani. Mr. Dewansh Vasani is identified as the brother's son of Mr. Atul Vasani. The necessary information regarding these appointments was submitted in accordance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The Board confirmed that none of the directors are debarred from holding the office of Director by virtue of any SEBI order or other authority.